Sanofi
SAN
Rang in Aktien
#225
Sanofi is a global healthcare enterprise dedicated to the research,... Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.
Aktienkurs
$83.84
Marktkapitalisierung
$100.45B
Veränderung (1 Tag)
1.48%
Veränderung (1 Jahr)
-16.74%
Land
FR
Handel Sanofi (SAN)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Sanofi (SAN)
Anzahl der ausstehenden Aktien zum June 2026: 1.20B
Laut den neuesten Finanzberichten und dem Aktienkurs von Sanofi beträgt die aktuelle Anzahl der ausstehenden Aktien 1.20B. Am Ende von December 2024 hatte das Unternehmen 1.25B ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Sanofi (SAN) von 2001 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 1.20B | -1.95% |
| 2025 | 1.22B | -2.48% |
| 2024 | 1.25B | -0.02% |
| 2023 | 1.25B | -0.02% |
| 2022 | 1.25B | -0.05% |
| 2021 | 1.25B | -0.09% |
| 2020 | 1.25B | 0.30% |
| 2019 | 1.25B | 0.22% |
| 2018 | 1.25B | -0.78% |
| 2017 | 1.26B | -2.31% |
| 2016 | 1.29B | -1.50% |
| 2015 | 1.31B | -0.73% |
| 2014 | 1.32B | -0.55% |
| 2013 | 1.32B | 0.27% |
| 2012 | 1.32B | -0.17% |
| 2011 | 1.32B | 1.26% |
| 2010 | 1.31B | -0.09% |
| 2009 | 1.31B | -0.22% |
| 2008 | 1.31B | -2.79% |
| 2007 | 1.35B | 0.01% |
| 2006 | 1.35B | 0.77% |
| 2005 | 1.34B | 46.82% |
| 2004 | 910.30M | 29.53% |
| 2003 | 702.75M | -3.43% |
| 2002 | 727.69M | -0.55% |
| 2001 | 731.71M | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 892.40M | -25.42% |
US
|
|
| 2.45B | 104.54% |
US
|
|
| 1.77B | 48.00% |
US
|
|
| 0.00 | -100.00% |
US
|
|
| 809.26M | -32.37% |
CH
|
